• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ESTABLISHMENT LABS S.A. MOTIVA SILKSURFACE PLUS; MOTIVA IMPLANTS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ESTABLISHMENT LABS S.A. MOTIVA SILKSURFACE PLUS; MOTIVA IMPLANTS Back to Search Results
Catalog Number RSF-355+
Medical Device Problem Code Device Appears to Trigger Rejection (1524)
Health Effect - Clinical Code Capsular Contracture (1761)
Date of Event 02/20/2025
Type of Reportable Event Serious Injury
Event or Problem Description
Chile- patient presented pain and asymmetry on her right breast and was diagnosed with capsular contracture baker grade iii according to ultrasound findings.She was advised to undergo explantation surgery.No patient demographics, age, weight, or ethnicity, were provided by the reporter, and no adverse outcomes for the patient have been noted.Efforts to gather additional information are being made and the investigation remains in progress.
 
Additional Manufacturer Narrative
The most common overall indication for reoperation is capsular contracture (handel, 2006).Breast prostheses are no different from any foreign material implanted into the human body in the sense of triggering a protective immune reaction from the host.This ¿foreign body response¿ (fbr) is universal and ideally removes or otherwise surrounds the ¿irritant material¿ with fibrous tissue to prevent unwanted immune sequelae.A capsule around a breast implant is, therefore, a necessary mechanism of body defense, but if excessive it can lead to pain and deformity of the breast (steiert, et al., 2013).Per our directions for use, each patient must receive the establishment labs s.A.¿motiva implants®: information for the patient¿ during her surgical consultation, it is the surgeons´ responsibility to ensure that the patient completely understands the information regarding the risks, benefits, and recommendations associated with silicone gel-filled breast implant surgery, as well as the complications typical of any type of surgery.This document is available in motiva® website: ifu.Motiva.Health.The instructions for use in the directions for use were reviewed, to determinate if there are indications that ensure the prevention and good handling of the product.For this event, it is considered that the information is suitable for the section of surgical precautions as follows: ¿capsular contracture occurs when the capsule tightens and squeezes the implant.This can cause the implant to turn rigid (from slightly firm to quite hard) and the firmest ones can cause varying degrees of discomfort, pain, and palpability.In addition to the firmness, capsular contracture can result in a deformed breast, visible surface wrinkling and/or displacement of the implant.Detection of breast cancer by mammography may also be a more difficult.Capsular contracture may be more common following infection, hematoma, and seroma, and the chance of it happening may increase over time.Capsular contracture is a risk factor for implant rupture, and it is the most common reason for reoperation in augmentation and reconstruction patients.Patients should also be advised that additional surgery might be needed in cases where pain and/or firmness are severe (baker grades iii or iv) and that capsular contracture may happen again after additional surgeries."correction of capsular contracture may require surgical removal or release of the capsule, or removal and possible replacement of the implant itself¿.In addition, a review of the device history record was conducted, and it was concluded that there were no deviations in the manufacturing process of this device that would have caused or contributed to this incident.
 
Additional Manufacturer Narrative
After an analysis of the clinical evidence provided and the report, it was possible to confirm the unilateral capsular contracture.The alleged event is a risk associated with breast surgery and there is no evidence to suggest a link between this particular implant and/or its manufacturing process and a higher risk of occurrence.The cause of this event is multifactorial, and we cannot conclude that the reported event was caused by the manufacturing process and/or the product itself.Establishment labs will continue to monitor for similar complaints/trends.As part of the post market surveillance process, monitoring of the primary endpoints reported is performed to determine unfavorable trends.Per our current complaint data report, no unfavorable trends were detected on this product.No further actions are required.
 
Event or Problem Description
Chile- patient presented pain and asymmetry on her right breast and was diagnosed with capsular contracture baker grade iii according to ultrasound findings.She was advised to undergo explantation surgery.No patient demographics, age, weight, or ethnicity, were provided by the reporter, and no adverse outcomes for the patient have been noted.Efforts to gather additional information are being made and the investigation was completed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MOTIVA SILKSURFACE PLUS
Common Device Name
MOTIVA IMPLANTS
Manufacturer (Section D)
ESTABLISHMENT LABS S.A.
building b-25, coyol free zone
alajuela,alajuela
Manufacturer (Section G)
ESTABLISHMENT LABS S.A.
building b-25, coyol free zone
alajuela,alajuela
Manufacturer Contact
susana hidalgo
building b-25, coyol free zone
alajuela,alajuela 
8003554164
MDR Report Key21567116
Report Number3012883202-2025-00460
Device Sequence Number11855514
Product Code FTR
UDI-Device Identifier07445161002105
UDI-Public(01)07445161002105(11)220620(17)270620
Combination Product (Y/N)N
Initial Reporter CountryUS
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2022
Device Explanted Year2025
Reporter Type Manufacturer
Report Source Foreign
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 05/06/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Catalogue NumberRSF-355+
Device Lot Number22061009
Is the Reporter a Health Professional? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 03/03/2025
Supplement Date Received by ManufacturerNot provided
Initial Report FDA Received Date03/10/2025
Supplement Report FDA Received Date05/06/2025
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured06/20/2022
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient SexUnknown
-
-